S&P 500
5.011,12 -11,09 (-0,22%) Nasdaq
15.601,50 -81,87 (-0,52%) NIKKEI 225
37.060,06 -1.019,64 (-2,68%) Dólar/Euro
1,0641 -0,0006 (-0,05%) Petróleo Brent
88,94 +1,83 (+2,10%) Bitcoin EUR
58.469,16 +446,36 (+0,77%)
AstraZeneca PLC (AZN)
Después del cierre:
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com
Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 89.900
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Executive Director | 5,68M | N/A | 1959 |
| Dr. Aradhana Sarin M.D. | CFO & Executive Director | 3,13M | N/A | 1974 |
| Ms. Pam P. Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | N/A | N/A | 1970 |
| Mr. Andrew P. Barnett | Head of Investor Relations | N/A | N/A | N/A |
| Mr. Jeffrey Pott | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | N/A | N/A | N/A |
| Gonzalo Vina | Head of Global Media Relations | N/A | N/A | N/A |
| Dr. Menelas Nicolas Pangalos Ph.D. | Executive Vice-President | N/A | N/A | 1967 |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit | N/A | N/A | N/A |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Research & Development | N/A | N/A | 1966 |
| Mr. Leon Wang | Executive VP of International & China President | N/A | N/A | N/A |
Descripción
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Gobierno corporativo
El ISS Governance QualityScore de AstraZeneca PLC, a día 1 de abril de 2024, es 9. Las puntuaciones base son Auditoría: 5; Tablero: 3; Derechos de los accionistas: 9; Compensación: 9.
